Anlotinib for Esophageal Cancer (AFEC)

Anyang Tumor Hospital200 enrolled

Overview

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Esophageal Cancer

Interventions

AnlotinibDRUG

This is an observational study

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age: ≥ 18 years old, male or female; 2. Patients with esophageal cancer were diagnosed; 3. Patients assessed by doctors to benefit from single or combined treatment of arotinib; 4. Patients volunteered to join the project. Exclusion Criteria: None

Locations (1)

Anyang Cancer Hospital

Anyang, China

RECRUITING

Outcomes

Primary Outcomes

Overall Survival

Time frame: From date of admission until the date of death from any cause, assessed up to 24 months

Secondary Outcomes

PFS

Progression Free Survival

Time frame: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Central Contacts

Junsheng Mr Wang, doctor

CONTACT

0086-15950527350 junsheng20210616@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.